MEDIWOUND LTD
MDWDNASDAQTrading Snapshot
- Day Range
- $13.71 – $14.05
- 52-Week Range
- $12.52 – $20.03
- Volume
- $2.87B
- Avg Volume
- $2.99B
- Shares Outstanding
- 12.8M
- Next Earnings
- Dec 3, 2026
Fundamentals Snapshot
- Annual Revenue
- $17M
- Last Q Revenue
- $3M
- P/E Ratio
- -8.6
- P/S Ratio
- 15.0x
- EPS (TTM)
- $-1.57
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +18.9%
Why Investors Own MDWD
- ✓High-growth profile — revenue up -5.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 65% gross margin and 8% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
MEDIWOUND LTD
MDWD
StockOtter · stockotter.spaceAbout MEDIWOUND LTD
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid®
MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid ®
Independent DSMB Recommends MediWound's EscharEx® Phase III VALUE Study Continue Without Modification
Independent DSMB Recommends MediWound's EscharEx ® Phase III VALUE Study Continue Without Modification DSMB did not identify safety concerns in pre-specified review; interim assessment and enrollment completion remain on
MediWound to Present at the H.C. Wainwright 28th Annual Global Investment Conference
MediWound to Present at the H.C. Wainwright 28 th Annual Global Investment Conference YAVNE, Israel, September 2, 2026 -- MediWound Ltd.
MediWound Ltd. (MDWD) Q2 2026 Earnings Call Transcript
MediWound Ltd. (MDWD) Q2 2026 Earnings Call Transcript
MediWound Q2 Earnings Call Highlights
MediWound NASDAQ: MDWD reported second-quarter 2026 revenue of $3.1 million, down from $5.7 million a year earlier, as the company continued investing in its Phase III EscharEx chronic-wound program and expanded developm
MediWound (MDWD) Reports Q2 Loss, Beats Revenue Estimates
MediWound (MDWD) came out with a quarterly loss of $0.77 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to a loss of $1.23 per share a year ago.